30 jul: ThyssenKrupp's Cromme Rules Out Merger with Siemens - Re..
30 jul: Manila Electric Chairman: 2012 Core Profit Guidance Raised to PHP..
30-07-2012 08:45:00

Reckitt Benckiser Warns on Mature Markets as Profit Rises

Relateret indhold
Relateret debat
14 sep - 
Hej Robin Jeg har investeret i færre virksomheder end d..
14 sep - 
Hej Tak for jeres kommentar. Oekonomen: Du har helt ret..
14 sep - 
hermed min portefølje og dermed mit bud på en solid por..

By Simon Zekaria

LONDON--Reckitt Benckiser PLC (RB.LN) Monday warned on a tough outlook for consumer spending in mature markets as it posted a slight rise in profit, helped by demand for household and medical products in emerging markets.

"While the consumer and competitive environment in Europe and North America remains challenging, we are doing the right things for the long term," said Chief Executive Rakesh Kapoor.

The U.K.-based maker of Air Wick air freshener, Dettol disinfectant and Neurofen pain relief tablets said net profit in the six months to June 30 rose 2.6% to GBP779 million ($1.22 billion) from GBP759 million a year earlier. Revenue in the period rose to GBP4.67 billion from GBP4.62 billion.

Second-quarter revenue fell 1.1% to GBP2.31 billion from GBP2.34 billion, missing market expectations from a company poll of GBP2.35 billion. However, like-for-like revenue rose 4%.

Unilever NV (UN) last week warned consumer companies are operating in a deteriorating global economy as it reported a small drop in net profit, while U.S.-based market leader Procter & Gamble Co. (PG) has issued two profit warnings this year, blaming weak demand in mature markets where spending is squeezed.

Rising middle-class populations with increased spending power in countries like Brazil, India and Indonesia are driving demand for high-margin health and hygiene goods. In contrast, Western economies, particularly in Europe, are seeing a cutback in consumer purchases amid weak economic conditions.

Earlier this year, Reckitt announced plans to merge its North American and European operations in a bid to focus investment and resources in emerging markets. Its goal is to generate half of its sales in developing economies, excluding food and pharmaceuticals, by 2016, up from just over 40% currently.

The move is aimed at reversing a recent slowdown in business. Last year saw the departure of CEO Bart Becht, the man credited with delivering consistent profit growth and more than quadrupling the company's share price since taking over in 1999. His replacement, Mr. Kapoor, is now tasked with guiding the company through an increasingly turbulent market.

Slough, England-based Reckitt Benckiser, which makes products as diverse as French's yellow mustard and Suboxone, a heroin addiction treatment, is aiming for comparable full-year revenue, excluding its pharmaceutical operations, to exceed forecast market growth of 1% to 2% by two percentage points, and to sustain this trajectory in the medium term. Excluding pharmaceuticals, it aims to maintain its operating margins.

It recommended an interim dividend of 56 pence a share, up 2% year-on-year.

Reckitt Benckiser shares closed Friday at 3542 pence, valuing the company at GBP25.61 billion, up 11% in the year to date.

Write to Simon Zekaria at simon.zekaria@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 30, 2012 02:45 ET (06:45 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
14 sep
PG
Hej Robin Jeg har investeret i færre virksomheder end du. Til gengæld søger jeg at mindske min risi..
1
14 sep
PG
hermed min portefølje og dermed mit bud på en solid portefølje.     Aktie Vægtning ▴      ..
1

Fondsbørsmeddelelser

Maersk Line-chef tager på charmeoffensiv i Kina

19-09-2014 15:47:03
Den administrerende direktør for Maersk Line, Søren Skou, har besøgt de kinesiske myndigheder i et forsøg på at skaffe opbakning til en ny shipping-alliance med..

Novo/Sydbank: Novo sidder tungt på diabetes-tronen

19-09-2014 12:17:21
Sydbank fastholder sin anbefaling af Novo Nordisk-aktien til trods for, at den amerikanske lægemiddelstyrelse, FDA, torsdag aften har godkendt Novo-konkurrenten..

Novo: Nygodkendt diabetesmiddel giver lynhurtigt effekt

19-09-2014 11:31:02
Novo Nordisks nye kombinationspræparat til behandling af type 2 diabetes, Xultophy, yder allerede efter fire uger en betydelig blodsukkerkontrol.Det fremgår af ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/Jyske: Svagt momentum bag lavere kursmål
2
Aktier/åbning: C20 styrer mod rekord efter skotsk afstemning
3
Novo får godkendt kombinationsmidlet Ideglira i EU
4
Aktier/tendens: Skotsk afstemning løfter stemningen
5
Aktier/middag: Skotterne sender Vestas og C20 til vejrs

Relaterede aktiekurser

Procter & Gamble Co 84,47 0,3% Stigning i aktiekurs
Unilever DR 31,43 0,2% Stigning i aktiekurs
Unilever PLC Ord 3 1/9p 2.604,00 -0,3% Fald i aktiekurs
Reckitt BEN GP ORD 2000P 5.384,59 -0,4% Fald i aktiekurs
Unilever PLC 42,56 -0,4% Fald i aktiekurs
Unilever N.V. 40,37 -0,3% Fald i aktiekurs
Procter Gamble 65,49 0,3% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. september 2014 02:09:49
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140919.1 - EUROWEB4 - 2014-09-20 02:09:49 - 2014-09-20 02:09:49 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x